ArticleCellular oncology (Dordrecht, Netherlands)2026
Integrative analysis and functional validation identified palmitoylated PHGDH as a therapeutic target for colon adenocarcinoma.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundColon adenocarcinoma (COAD) has high incidence and mortality with poor prognosis, creating an urgent need for novel prognostic models and therapeutic strategies. Protein palmitoylation, an important post-translational modification, exerts pivotal effects on tumorigenesis; however, its prognostic and mechanistic relevance in COAD remains unknown. This study determined palmitoylation-related prognostic biomarkers and probable therapeutic targets to treat COAD.
methodsWe integrated transcriptomic datasets from the TCGA and identified prognostic genes related to palmitoylation by conducting differential expression analysis, weighted gene correlation network analysis, and Cox proportional hazards modeling using the least absolute shrinkage and selection operator (LASSO) method. Based on these genes, we established a robust risk signature and nomogram that consistently stratified COAD patients into distinct risk groups. Multi-omics profiling, including immune infiltration assessment, drug response prediction, and single-cell mapping, revealed distinct molecular and cellular programs within each risk group. In vitro and in vivo studies were conducted using the representative hub gene PHGDH to validate its function in COAD.
resultsA risk score model comprising three palmitoylation-related genes (PHGDH, LAMA2, and PBXIP1) stratified COAD patients into subgroups with distinct survival, immune infiltration, and drug sensitivity profiles. PHGDH was identified as the most dysregulated candidate. Functional studies revealed that depleting PHGDH significantly repressed cell proliferation and induced apoptosis. Critically, pharmacological inhibition of PHGDH palmitoylation markedly suppressed tumor growth in vitro and in xenograft models, indicating its feasibility as a therapeutic target for COAD.
conclusionThe palmitoylation-related risk model established in this study demonstrates strong prognostic predictive capability for COAD, offering a promising new clinical stratification tool. Furthermore, PHGDH was validated as a key functional target whose activity is regulated by palmitoylation, presenting a novel therapeutic opportunity for COAD treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.